Literature DB >> 15790318

Rheumatic fever: the relationship between clinical manifestations and laboratory tests.

S Roodpeyma1, Z Kamali, R Zare.   

Abstract

OBJECTIVES: To determine the relationship between the severity of clinical features of rheumatic fever (RF), and antistreptolysin O titre (ASOT) and/or erythrocyte sedimentation rate (ESR).
METHODS: Clinical and laboratory data from 102 children with RF who had been admitted at a university hospital in Tehran between 1992 and 2002 were reviewed retrospectively. In order to categorize the severity of clinical manifestations of disease, patients were divided into three groups. Those with arthritis alone were defined as group A, carditis with or without arthritis as group B and carditis (with or without arthritis) with congestive heart failure as group C.
RESULTS: Thirty-one cases were enrolled in group A, 39 in group B, and 32 in group C. We didn't find a significant relationship between the severity of clinical presentation of disease and ASOT (P = 0.89) and ESR (P = 0.24). Seventy-two patients presented with first attack and 30 had recurrences. The frequency of congestive heart failure (CHF) in first attacks was 31.2%vs 68.8% in recurrences (P < 0.0001). No Significant relationship was found between the number of involved valves and ASOT (P = 0.4) or ESR (P = 0.8).
CONCLUSION: Variable clinical presentation of disease and increasing intensity of cardiac involvement is not related to the ASOT or ESR levels.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15790318     DOI: 10.1111/j.1440-1754.2005.00557.x

Source DB:  PubMed          Journal:  J Paediatr Child Health        ISSN: 1034-4810            Impact factor:   1.954


  3 in total

1.  Antistreptolysin O titer in health and disease: levels and significance.

Authors:  Alyaa Amal Kotby; Nevin Mamdouh Habeeb; Sahar Ezz El Elarab
Journal:  Pediatr Rep       Date:  2012-02-09

2.  Subclinical rheumatic heart disease: A single center experience.

Authors:  Seyma Kayali; Nuran Belder
Journal:  North Clin Istanb       Date:  2018-08-13

3.  How Many Doses Make a Difference? An Analysis of Secondary Prevention of Rheumatic Fever and Rheumatic Heart Disease.

Authors:  Jessica Langloh de Dassel; Nick de Klerk; Jonathan Rhys Carapetis; Anna P Ralph
Journal:  J Am Heart Assoc       Date:  2018-12-18       Impact factor: 5.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.